28 April 2023: Aker BioMarine ASA ("Aker BioMarine" or "the company") reports
revenues of USD 69 million and Adjusted EBITDA of USD 6.0 million for the first
quarter 2023. 

Highlights first quarter:
- Revenues of USD 69.0, up 22% year over year
- Adjusted EBITDA of USD 6.0 million, down from USD 8.1 million last year
- Krill offshore production stable YoY at 19,852 MT (20,809 MT) 
- Revenues in the Ingredients segment of USD 41.6 million, up 38% YoY
- Revenues in the Brands segment of USD 33.5 million, up 10% YoY
- Event after the quarter end: Final approval for the Superba health claim in
the South Korean market- preparing for re-launch in second quarter.

"Aker BioMarine delivers sales growth in all segments compared to the same
quarter last year. Our krill oil product Superba continued the positive sales
trend, driven by good development in Asia, Europe and US mass market. On back of
this it is exciting to announce the approval for Superba as Health Functional
Food in the South Korean market, and we will now re-launch marketing and sales
together with our long-term local partner. Our harvesting fleet are performing
well, and we are tracking on par with the strong beginning of last year.", said
Matts Johansen, CEO of Aker BioMarine.


Outlook
For second quarter 2023 we expect Qrill Aqua and Superba revenues, as well as
Brands revenues to be above same quarter last year. We also expect Superba sales
in second quarter to be on par or above with first quarter 2023.

We expect long-term average annual sales growth for Aker BioMarine to be in line
with earlier communicated ambitions at around 15%.

At 09:00 CET today, the management hosts a webcast. Following the presentation,
there will be a Q&A session, where written questions can be submitted to
ir@akerbiomarine.com.

The webcasted presentation will be in English. To join, please use the link that
is available at www.akerbiomarine.com/investor. 

A replay of the presentation and Q&A session material will be made available
soon after the presentation at the same web address.

For further information, please contact 
Katrine Klaveness, CFO
Mobile: +47 991 58 915
Email:  Katrine.Klaveness@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.